Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration

BETHESDA, Md. and BALTIMORE, Nov. 30, 2020 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”), today announced a research collaboration with the University of Maryland School of Medicine (UMSOM), to investigate Gain’s structurally targeted allosteric regulators (STARs) in cellular models of neuronopathic Gaucher disease (nGD) and Parkinson’s disease (PD). STARs are proprietary small molecules targeting novel allosteric binding sites on enzymes. These small molecule drug candidates are designed to cross the blood brain barrier and penetrate other hard to treat organs such as bone and cartilage, stabilize the effective enzyme to restore function and reduce toxic substrate. Research will be led by Ricardo A. Feldman, Ph.D., Associate Professor, of Microbiology and Immunology in UMSOM.

Under the terms of the collaboration, UMSOM will investigate Gain’s STAR candidates in macrophage and neuronal models of nGD and GBA -associated PD. These diseases are characterized by mutations in the GBA gene, where misfolding of the enzyme encoded by GBA (beta-glucocerebrosidase (GCase)) interferes with its normal transport to the lysosome. The research program will aim to further elucidate the mechanism of action of Gain’s STAR candidates by studying their effect on GCase, including GCase’s enzyme activity and transport to the lysosome. Additionally, other effects such as prevention of alpha-synuclein aggregation in PD dopaminergic neurons will be evaluated.

“We are exceedingly proud to be advancing our work in nGD and Parkinson’s in close collaboration with the University of Maryland School of Medicine,” said Eric Richman, Chief Executive Officer at Gain. “The expertise and experience of UMSOM and Dr. Feldman will be instrumental as we work to further validate the exciting potential of Gain’s STAR candidate for these devastating diseases. I am confident these foundational studies will bring us closer to a potential new treatment option for those with these disorders.”

Dr. Feldman added, “Our laboratory has used human induced pluripotent stem cell (iPSC) models of GD and GBA -associated PD to uncover the molecular mechanisms leading to these diseases. We have also developed very sensitive assays to evaluate the therapeutic efficacy of small molecules in reversing the phenotypic abnormalities caused by mutant GBA in the cell types affected by these diseases, including macrophages and neuronal cells. I have been impressed by Gain’s initial results evaluating the potential of STARs in correcting enzyme misfolding and restoring function, and look forward to working with Gain’s team to further advance its program to treat these diseases.”

Gain and UMSOM intend to report initial data from the collaboration in the first half of 2021.

About Gain Therapeutics, Inc.
Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research

Read more

After Last Week’s Gain, Should You Consider Investing In MGM Resorts’ Stock?

MGM Resorts International (NYSE: MGM) gained nearly 12% in the last 5 trading days. Despite this move, the stock is still nearly 20% below where it was at the beginning of 2020. What does this mean? Simply that big money is pouring into MGM Resorts and other stocks that are likely to benefit the most with the success of a Covid-19 vaccine, but at the same time, the market price appears relatively low. Does this imply that MGM is a good buy right now? Our AI engine certainly suggests so, and so do the fundamentals! Let’s see how. Our AI engine analyzes past patterns in stock movements to predict near term behavior for a given level of movement in the recent period, and predicts nearly a 4.2% return for MGM Resorts over the next 1 month. But that doesn’t mean that the stock will lose its steam beyond that. In fact, the same engine predicts more than an 11% return during the next 6 month period. Our detailed dashboard highlights the expected return for MGM Resorts International’ given its recent move.

But what about the fundamentals? Our dashboard Big Movers: MGM Resorts International Moved 12.2% – What Next? lays this out, outlining MGM’s consistent pre-Covid growth and cheaper multiple relative to peers. Unless there is a meaningful setback concerning vaccine distribution or efficacy, MGM could be a good investment right now.

Let’s look at relative valuation perspective first. MGM Resorts International’s stock price decreased -27% this year, from $33.27 to $23.98, before moving 12.2% last week, and ending at $26.91. At the beginning of this year, MGM Resorts International’s trailing 12 month P/S ratio was 1.35. This figure increased 11.5% to 1.51, before ending at 1.69. This means that valuation has not declined proportionately to its revenue, implying the long-term investor expectations are intact. Also, compared to MGM Resorts International’s P/S multiple of 1.69, the figure for its peers MTN, CHDN, and SIX stands at 5.47, 6.13, and 1.58 respectively. This indicates room for valuation to grow.

If we look at the last few years, we find that MGM Resorts’ stock has decreased -0.4% between 2017 and 2019, and has decreased -19% between 2017 and now. Thus, its last week’s move is slightly at odds with the long-term trend which raises

Read more

To gain an edge on hypersonic weapons, the Pentagon wants more help from universities

WASHINGTON — As the Pentagon races to develop hypersonic weapons, it is turning to universities for help on speeding up the transfer of technology from the laboratory to the field.

The Defense Department on Oct. 26 tapped Texas A&M University to create and manage a University Consortium for Applied Hypersonics. Over a five-year period, the department will pay out $20 million per year to the university’s Engineering Experiment Station, it said in a statement.

Greater interplay among government, academia and industry is needed to better integrate the various state-of-the art technologies necessary to create hypersonic weapons, which require novel propulsion systems and advanced materials that can withstand the extreme conditions intrinsic to flying five times the speed of sound, said Gillian Bussey, director of the Pentagon’s Joint Hypersonics Transition Office.

“The department is funding a good amount of basic research in hypersonics,” she said. “But we’re finding that tests leading some of the more applied areas,” which supports the transfer of technologies into manufactured products, “are not quite as healthy and not bringing fresh blood into our work force and into our industry.”

The new consortium will work directly with the Defense Department and other government agencies on hypersonic research, with a focus on partnering with industry to transition new technologies into programs of record.

Bussey pointed to hypersonic development activities in China, where academic research papers show that college students are being exposed to every element of hypersonic vehicle development, from design to flying experimental prototypes in windtunnel tests.

The U.S. consortium will start working on challenge projects, where a military agency like the Office of Naval Research designates a problem for the university to solve. Those problems could potentially involve classified or controlled technologies.

“The gold standard [for the U.S. university consortium] would be to have the team develop a vehicle and fly it. That really depends on our budget and how things go,” Bussey said.

The consortium is set to begin operations this fall and will be led by Rodney Bowersox, an aeronautical engineering professor at Texas A&M and director of the university’s hypersonics laboratory.

A board of experts — with members from the Massachusetts Institute of Technology, the University of Minnesota, the University of Illinois at Urbana-Champaign, the University of Arizona, the University of Tennessee Space Institute, Morgan State University, the California Institute of Technology, Purdue, the University of California-Los Angeles, and the Georgia Institute of Technology — will also provide guidance to the new organization.

Developing and fielding hypersonic weapons has been a major priority for the Defense Department officials, who have raised concerns about Chinese and Russian advances in that realm. Last week, national security adviser Robert O’Brien announced that the Navy’s Virginia-class submarines, Zumwalt-class destroyers and Arleigh Burke-class destroyers would all eventually be able to launch hypersonic missiles.

“We do believe we are in a bit of a race right now,” said Mark Lewis, the department’s director of research and engineering for modernization. “We had previously a number of a prototype

Read more